

Most Human Non-GCIMP Glioblastoma Subtypes Evolve from a Common Proneural-like Precursor Glioma

Tatsuya Ozawa,^{1,7} Markus Riester,^{2,3,7} Yu-Kang Cheng,^{2,3} Jason T. Huse,⁴ Massimo Squatrito,⁵ Karim Helmy,⁶ Nikki Charles,⁶ Franziska Michor,^{2,3,8,*} and Eric C. Holland^{1,8,*}

¹Division of Human Biology and Solid Tumor Translational Research, Fred Hutchinson Cancer Research Center, Department of Neurosurgery and Alvord Brain Tumor Center, University of Washington, Seattle, WA 98109, USA

²Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute

³Department of Biostatistics

Harvard School of Public Health, Boston, MA 02215, USA

⁴Department of Pathology and Human Oncology, Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

⁵Cancer Cell Biology Programme, Spanish National Cancer Research Centre, Madrid 28029, Spain

⁶Department of Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

⁷Co-first author

⁸Co-senior author

*Correspondence: michor@jimmy.harvard.edu (F.M.), eholland@fhcrc.org (E.C.H.)

<http://dx.doi.org/10.1016/j.ccr.2014.06.005>

SUMMARY

To understand the relationships between the non-GCIMP glioblastoma (GBM) subgroups, we performed mathematical modeling to predict the temporal sequence of driver events during tumorigenesis. The most common order of evolutionary events is 1) chromosome (chr) 7 gain and chr10 loss, followed by 2) *CDKN2A* loss and/or *TP53* mutation, and 3) alterations canonical for specific subtypes. We then developed a computational methodology to identify drivers of broad copy number changes, identifying *PDGFA* (chr7) and *PTEN* (chr10) as driving initial nondisjunction events. These predictions were validated using mouse modeling, showing that *PDGFA* is sufficient to induce proneural-like gliomas and that additional *NF1* loss converts proneural to the mesenchymal subtype. Our findings suggest that most non-GCIMP mesenchymal GBMs arise as, and evolve from, a proneural-like precursor.

INTRODUCTION

Glioblastomas (GBMs) are the most common and malignant CNS neoplasms and arise initially as grade 4 tumors (primary GBM) or evolve from lower-grade gliomas (secondary GBM). Deep molecular analyses of primary GBMs have divided them into four classes: proneural (PN), mesenchymal (MES), classical (CL), and neural (NL) (Brennan et al., 2009; Phillips et al., 2006; Verhaak et al., 2010). However, in some cases, the division is blurred in that a sample might show patterns of more than one subtype (Brennan et al., 2009; Phillips et al., 2006; Sottoriva et al., 2013; Verhaak et al., 2010). These subclasses can be asso-

ciated with canonical mutations such as *PDGFRA* amplification in PN GBM, loss of *NF1* in MES GBM, and amplification of *EGFR* in CL GBM. In the case of NL GBMs, particular molecular abnormalities remain unidentified.

One of the best-studied GBM subclasses is PN GBM, some of which carrying mutant *IDH1* or *IDH2* and have the methylator phenotype denoted by glioma-CpG island methylator phenotype (GCIMP) (Noussim et al., 2010). Although the transcriptomal patterns for GCIMP tumors resemble those of the other PN GBMs (non-GCIMP), their biology is significantly different in that the GCIMP GBMs display global hypermethylation of CpG islands, characteristic copy number

Significance

Deep molecular analyses have divided non-GCIMP GBMs into four classes, but the relationship between these subtypes is unknown. Here we combined computational and mathematical analyses of human GBM data with mouse modeling and found that these tumors appear to be initiated by broad genomic alterations driven partly by increased *PDGFA* expression and *PTEN* loss and evolve from a common glioma precursor that is lethal and proneural in character. The acquisition of secondary molecular subtype characteristics by *EGFR* and *PDGFRA* amplification or *NF1* loss is achieved late in GBM evolution. Our findings provide insights into the natural history of GBMs and therapeutic strategies targeting these late events.

alterations, and prolonged patient survival, suggesting that these tumors represent high-grade versions of grade 2 and 3 diffuse gliomas, which are commonly GCIMP and, thus, represent secondary GBMs (Noushmehr et al., 2010; Ohgaki and Kleihues, 2013).

The existence of different GBM subtypes raises questions regarding their natural history and the temporal sequence in which individual alterations arise (Bhat et al., 2013; Phillips et al., 2006; Sottoriva et al., 2013). Furthermore, it is unclear whether these subgroups are fundamentally different tumors from their inception or whether they evolve from a common glioma precursor. Given the evidence of spontaneous conversion of human PN to MES tumors and observed subtype mosaicism within the same tumor (Phillips et al., 2006; Sottoriva et al., 2013), the GBM subtypes might be directionally variable from one subtype to another. Finally, it remains unclear whether the existence of subgroups has therapeutic implications (Bhat et al., 2013). For example, the subtype-defining mutations may be promising therapeutic targets if they represent initiating genetic events in glioma evolution, but their inhibition would likely not provide a lasting therapeutic benefit if they represent late events.

Chromosome instability is common in human cancers. It is characterized by widespread chromosome (chr) copy number changes, such as gain or loss of whole chr or fractions thereof (Lengauer et al., 1998). Gain of chr7 as well as loss of chr10 and parts of chr9 are very frequent in gliomas. Alteration of chr7 frequently includes focal amplification of the *EGFR* locus (The Cancer Genome Atlas Research Network, 2008). Nevertheless, forced expression of the wild-type epidermal growth factor receptor (EGFR) or the constitutively active EGFRvIII mutant alone does not form gliomas in mice (Holland et al., 1998; Zhu et al., 2009), suggesting that *EGFR* might not be an initiator of this tumor type.

Genome-wide high throughput sequencing efforts have led to the identification of many genomic alterations in cancer genomes, but it remains a challenge to identify genuine driver genes from the many genes located within a large chromosomal event. Here we utilized a combined computational and experimental approach to investigate the natural history of human non-GCIMP GBMs.

RESULTS

We first utilized genomic data from The Cancer Genome Atlas (TCGA) to investigate the frequencies and types of genomic alterations in GBM (The Cancer Genome Atlas Research Network, 2008). The overall pattern of broad gains and losses in the GCIMP tumors showed some similarities to that in the non-GCIMP PN GBM (Noushmehr et al., 2010) but were strikingly similar between the non-GCIMP PN GBM and other non-GCIMP subtypes (Figure 1A; Table S1 available online). These patterns suggest that all non-GCIMP GBMs are very similar with respect to genomic alterations acquired during their evolution and distinct from the GCIMP tumors. We then performed a phylogenetic analysis of copy number, mRNA expression, somatic mutations, and promoter methylation data of the non-GCIMP subgroups and found that PN GBMs located separately on the phylogenetic trees generated by each of these data types,

suggesting that they are distinct from other non-GCIMP subtypes (Figure 1B).

Gain of several copies of chr7 and loss of one copy of chr10 were the most frequent events in non-GCIMP GBMs, with frequencies of 86% and 90%, respectively (Figures 1A and 1C). GCIMP tumors almost never lose the entire chr10 but show similar frequencies of loss (26%) and amplification (24%) of 10p (Figures 1A and 1C). Note that gain of chr7 refers to the gain of a few copies of the whole chr7, which is different from amplification of any specific gene on chr7, and loss of chr10 refers to the loss of a whole copy of chr10 but leaving the other copy intact, which is not synonymous with focal deletion of any gene on chr10. These events are distinct from the commonly reported high-level amplification and deletion of specific genes in GBMs, such as *PDGFRA*, *EGFR*, or *MET* (The Cancer Genome Atlas Research Network, 2008).

When investigating 7p and 7q separately for all GBM subtypes, we found that 7p gain ranged from 81% for PN GBMs to 95% for MES GBMs, whereas 7q gain ranged from 79% for PN GBMs to 93% for MES GBMs (Figure 1C). In general, 7p and 7q gain were balanced (Figure 1D), with the exception of GCIMP tumors, in which 7q gain occurred in 24% of tumors and 7p gain in 15%. These data imply that, for non-GCIMP GBMs, chr7 is gained as the entire chromosome. Balanced chr7 gain is present in 82% of all non-GCIMP GBM samples and represents the most common chromosomal abnormality in these tumors. Non-GCIMP cases with a normal copy number of both chr7 and chr10 were rare (2%) (Figure S1A; Tables S2 and S3) and had a similar age and survival distribution as GCIMP tumors (Figures S1B and S1C), suggesting that some of these non-GCIMP cases are potentially misclassified GCIMP tumors (Figure S1D).

Mathematical Modeling Suggests Gain of Chr7 and Loss of Chr10 as First Events in All Non-GCIMP GBM Subtypes

The high prevalence and even distribution of chr7 gain and chr10 loss in all non-GCIMP GBM subtypes raises the question of when these events occur during GBM development. Therefore, we utilized a computational methodology, Retracing Evolutionary Steps in Cancer (RESIC), to determine the temporal sequence of genetic alterations during tumorigenesis from cross-sectional genomic data of a population of tumors at their fully transformed stage (see also Supplemental Experimental Procedures) (Attolini et al., 2010; Cheng et al., 2012). Applying RESIC to TCGA data (The Cancer Genome Atlas Research Network, 2008) to examine the temporal order of the known subtype-specific alterations *EGFR* (CL GBM), *NF1* (MES GBM), and *PDGFRA* (PN GBM) (Verhaak et al., 2010), together with gain of chr7 and loss of chr10, we identified chr7 gain together with chr10 loss as the first event in all subtypes of GBM (Figure 2A; Figures S2A and S2B). Loss of *CDKN2A* was another early event in all subtypes. Further analyses based on samples with mutational information only ($n = 85$ for non-GCIMP samples) revealed that *TP53* mutations arose after *CDKN2A* loss (Figure 2B; Figure S2C). Finally, when considering all frequent chromosome arm-level events, we found that chr7 gain and chr10 loss arise before any other broad gains or losses (Figure 2C; Figure S2D). An almost identical ordering of




Figure 1. Somatic Copy Number Alterations and Their Frequencies in GBM

(A) Genome plot visualizing frequencies of copy number gains (red) and losses (blue) along the genome in GCIMP tumors and the four non-GCIMP subtypes (proneural, neural, mesenchymal, and classical GBM).

(B) Phylogenetic analysis in all GBM samples determining the putative evolutionary order in GBM subtypes using all data types (copy number, mRNA expression, somatic mutation, and methylation) and the Neighbor Joining algorithm. Artificial samples with exactly two copies in the whole genome serve as a normal copy number control. For the DNA methylation analysis, the HM27 and HM450 platforms are shown.

(C) Histograms showing the frequencies of whole arm gains and losses of both chr7 and chr10 in each subtype separately. Homozyg., homozygous; Amp., amplification.

(D) Copy numbers of the p and q arms of chr7 and chr10 for all TCGA samples stratified by GBM subtype.

See also Figure S1 and Tables S1, S2, and S3.

these events was inferred using a different method (Beerenwinkel and Sullivan, 2009) (Figure S2E).

To delineate the clinical implications of these arm-level events, we investigated the association between chr7 gain or chr10 loss and GBM patient survival. Copy numbers of chr7 and chr10 correlate negatively and positively, respectively, with survival (Figures 3A and 3B). This finding arises primarily because these events do not occur as frequently in GCIMP tumors and because patients with these tumors survive longer, on average, than patients with non-GCIMP GBMs (Noushmehr et al., 2010). However, even in the non-GCIMP GBMs, chr7 gain correlates with poor survival of patients, but only in the case of PN GBM (Figure 3A). These data suggest that a gene or several genes on chr7 drive the gain of copy number early in GBM evolution and promote the aggressive character in PN GBM. By contrast, the lack of association of chr10 loss with overall survival might be due to haplosufficiency of genes on chr10 (Figure 3B).

Computational Analysis Suggests *PDGFA* and *PTEN* as Major Drivers of Nondisjunction Events

We aimed to identify the genes on chr7 and chr10 that drive the acquisition of these arm-level events, lead to the poor survival of patients, and are potential targets for therapies. We designed a computational algorithm consisting of two steps. The first step ranks genes based on the extent of correlation between their copy number and expression levels. Genes are first sorted by the fold change of expression between tumors that do and do not harbor the arm-level event. Genes with anticorrelation of copy number and mRNA levels are excluded. In the second step, the resulting gene list is filtered further by the degree of correlation between a gene's expression level and patient survival.

When applying the first step to genes on chr7 for all non-GCIMP GBM samples, we identified a set of genes with the highest expression response to increased copy number predicted to




Figure 2. Temporal Sequence of Events in Glioma Development

(A) Order of events for subtype-specific copy number alterations per subtype.

(B) Order of events for all GBM samples for which *TP53* point mutation data was available ($n = 85$).

(C) Order of chromosome level copy number alterations. Black ovals represent distinct mutational events. Arrows represent an ordering of events detected by RESIC. Rectangles containing events represent sets of events where RESIC could not distinguish an order of events. Black denotes orderings that are shared across subtypes. Red, yellow, green and blue denotes classical, mesenchymal, neural, and proneural subtype-specific orderings, respectively. Orderings shared by multiple subtypes, but not all subtypes, are denoted by multicolored arrows and rectangles. See also Figure S2.

occur with gain of chr7 (Table S4). Note that *EGFR* was not selected in this first filtering because a low-level gain of *EGFR*, as found with whole chr7 gain, is not correlated with its increased expression ($p = 0.19$, Student's *t* test, *EGFR* normal versus gain, Figure S3A). High-level amplification of *EGFR* is predicted by RESIC to be a late event (Figure 2A), and such focal amplification of *EGFR* correlates significantly with its expression level ($p < 0.001$, Student's *t* test, *EGFR* gain versus focal amplification, Figure S3A). Almost all identified point mutations in *EGFR* as well as in *EGFRvIII* were found in samples with high-level focal gene amplification (Figure S3A; Table S1). These data further support the hypothesis that *EGFR* may not be a driver of initial oncogenic events in this tumor type but, rather, contributes to tumor progression or maintenance through high expression driven by focal amplification arising at later stages of tumor formation.

The second step then showed that a direct correlation between expression levels and survival was uninformative because many genes on chr7 displayed a correlation between their copy number and expression. Thus, their expression also correlates with survival in PN GBM (Table S4). Therefore, we investigated the correlation between survival and the expression levels of pathways downstream of genes on chr7. When applying this filter to chr7, we found that, of the 190 genes whose expression fold change between cases of normal and gained chr7 copy number was at least 1.25, 13 genes displayed a correlation with survival in PN GBMs of $p < 0.05$ (Table S5). Figure 3C summarizes the two filters applied to chr7. This combined ranking approach identified *PDGFA* as the highest-ranking gene on chr7 (Figure S3B; Tables S5 and S6), i.e., expression of *PDGFA* downstream genes was associated with overall survival, and chr7 gain increased *PDGFA* mRNA levels significantly. Therefore, *PDGFA* most likely is the gene providing the strongest selective advantage to gaining extra copies of chr7.

We then sought to identify potential drivers of chr10 loss. The application of the two steps outlined above is only appropriate for chromosomal gains because the correlation between expression levels and patient outcomes necessitates a degree of variability in copy number across patients. Chr7 gain meets this requirement because patients may harbor three, four, or

more copies of chr7. By contrast, chr10 loss results in a single remaining copy of chr10 in almost all cases (Figures 1C and 1D), therefore necessitating an alternative strategy. Because loss of chr10 and gain of chr7 almost always co-occur ($p = 0.001$, Fisher's exact test, Figures 1A and 1C), we hypothesized that the phenotypic effect of a main driver of chr10 loss might amplify the effects of the driver of chr7 gain and vice versa, therefore likely activating the same pathways and resultant changes in gene expression. We also ranked the genes on chr10 by the association of the expression levels of their downstream genes with survival (Tables S4 and S5). The tumor suppressor *PTEN* displayed a highly significant survival association between the expression levels of its downstream genes and survival (false discovery rate [FDR] < 0.02) (Figure 3D; Figure S3C; Table S5) and also a large overlap of downstream genes of *PDGFA* (Figure 3E), suggesting that it may be a significant driver of chr10 loss in these tumors. In non-GCIMP GBM subtypes other than PN GBMs, we did not identify any such strong pathway enrichments of chr7 and chr10, consistent with the lack of correlation of chr7 gain with survival in these GBM subtypes (Figure 3A). Our computational approach therefore suggests *PDGFA* and *PTEN* as primary drivers of the chr7 and chr10 nondisjunction events, respectively. Note that this analysis does not suggest that these genes alone are sufficient for driving these events.

Mouse Modeling Suggests that the Predicted First Events in Glioma Evolution Are Sufficient to Induce Gliomagenesis

Our computational analyses predict that elevated expression of *PDGFA* represents the strongest initial driving event in glioma evolution. This is noteworthy because of the well described role of PDGF signaling in GBM, especially in PN GBM (Brennan et al., 2009; The Cancer Genome Atlas Research Network, 2008; Verhaak et al., 2010). Note that the elevated expression of *PDGFA* as a likely driver is not the same as the frequently reported high-level focal amplification of *PDGFRA* found primarily in PN GBM. The PDGF signaling network is transmitted by four ligands (A, B, C, and D isoforms) and two protein tyrosine kinase receptors (α and β). Overexpression of *PDGFB* generates *PDGFB*




Figure 3. Drivers of Chr7 and Chr10 Alterations in the Proneural Subtype

(A and B) Forest plots showing the hazard ratios (HR, squares) of chr7 gain (A) and chr10 loss (B) and their confidence intervals. HRs significantly larger than 1 (A) or lower than 1 (B) signify a copy number change associated with a poor prognosis. The square size is proportional to the sample size. (C and D) Genes on chr7 (C) and chr10 (D) ranked by association of downstream genes with overall survival, with the corresponding p values shown on the y axis. Genes were considered with a fold change (x axis) in expression of larger than 1.25 (averaged over both Affymetrix and Agilent platforms) when comparing patients with normal and altered chr7 and chr10 copy numbers. The top-ranking hits are shown in blue.

(E) The overlap in downstream genes of *PDGFA* in the Kyoto Encyclopedia of Genes and Genomes pathway database with the top-ranking genes on chr10 (x axis).

See also Figure S3 and Tables S4, S5, and S6.

homodimers (BB dimers) that activate both PDGFR α and β , whereas overexpression of PDGFA only activates PDGFR α (Andrae et al., 2008; Heldin and Westermark, 1999). In animal modeling systems, signaling driven by PDGFB alone is sufficient to form GBMs, and additional loss of *Tp53*, *Cdkn2a* (*Ink4a-Arf*), or *Pten* accelerates tumor formation (Dai et al., 2001; Fomchenko et al., 2011; Hu et al., 2005; Shih et al., 2004; Squatrito et al., 2010). Although the PDGFB protein level is elevated in many PN GBMs, it does not correlate with the PDGFB mRNA level in these tumors (Brennan et al., 2009). Moreover, the alteration of *PDGFB* is rare in GBMs (Verhaak et al., 2010), suggesting that other PDGFs, such as PDGFA, could potentially drive oncogenesis in this GBM subtype. However, it remains to be determined whether elevated PDGFA is sufficient to initiate gliomas, either alone or in combination with other early events such as *CDKN2A*, *TP53*, or *PTEN* loss (Figures 2A and 2B; Figures S3C and S3D) (Jackson et al., 2006; Nazarenko et al., 2011).

Therefore, we tested the ability of genes predicted to drive human GBM evolution to induce gliomas in vivo using the replication-competent avian sarcoma-leukosis virus long terminal repeat with splice acceptor/tumor virus a (RCAS/tv-a) system that allows postnatal cell type-specific gene transfer (Holland et al., 1998; Holland and Varmus, 1998). To determine whether PDGFA alone is sufficient for glioma formation, we infected neonatal *N/tv-a* mice (Nestin-expressing cell of origin, *n* = 11) and *G/tv-a* mice (GFAP-expressing cell of origin, *n* = 14) with an RCAS retroviral vector expressing human PDGFA (RCAS-PDGFA) (Figures S4A and S4B). All *N/tv-a* mice were sacrificed at 4 months of age, when the first mice developed symptoms of intracranial pathology. Eight of eleven mice harbored brain tumors of various sizes demonstrating histological features of grade 2 human oligodendrogliomas, including round nuclei, perinuclear halos, and strong Olig2 and lower GFAP expression (Fig-

ure 4A and data not shown). All *G/tv-a* mice formed tumors ranging from 159–323 days postinjection. Many developed high-grade gliomas with histologic features of human oligodendroglioma (Figure 4B; Figure S4C). These data indicate that elevated PDGFA expression is sufficient to initiate gliomagenesis in vivo.

***Pten* Loss Shortens Survival of Mice with PDGFA-Induced Gliomas but Is Not Sufficient to Induce Gliomas Alone**

RESIC analysis predicted that combined loss of chr10 and gain of chr7 are the earliest events in non-GCIMP GBM subtypes. Previous results using the RCAS/tv-a system have shown that loss of *Pten* alone is insufficient for glioma formation in mice (Hu et al., 2005), suggesting that loss of *Pten* might play a supportive role in PDGFA-responsive cells rather than serving as the tumor initiator. To confirm the supportive role of *Pten* loss in this context, we created an RCAS vector expressing mRFP and a short hairpin designed to knock down *Pten* expression (RCAS-shPten) (Figures S4A, S4D, and S4E). Infection of both wild-type *N/tv-a* (*n* = 3) and *G/tv-a* (*n* = 11) mice with this vector alone did not result in brain tumors by approximately 4 months of age. However, consistent with the RESIC prediction, simultaneous *Pten* loss significantly shortened the survival of mice with PDGFA-induced gliomas and elevated the grade of the tumors (Figures 4A and 4B; Figures S4F–S4H). These features were also observed in a cre-mediated *Pten* deletion model (Figure 4B; Figure S4F).

PDGFA-Induced Tumors Resemble PN GBMs, but PDGFB-Induced Tumors Display a More MES GBM-like Character

RESIC analysis also predicted that loss of *CDKN2A* occurs after gain of chr7 (elevation of PDGFA expression) in these tumors. Therefore, we injected neonatal *N/tv-a;Cdkn2a(Ink4a-Arf)*^{-/-} mice with RCAS-PDGFA (*n* = 25) (Figure 4C). Tumors occurred




Figure 4. PDGFA Induces Gliomas with Similar Expression Patterns as Human Proneural GBMs in Mice

(A–C) Kaplan-Meier survival curves showing symptom-free survival of PDGFA- or PDGFB-induced gliomas in *Nestin* (*N*)/*tv-a* (A), *GFAP* (*G*)/*tv-a*, or *G/tv-a;Pten^{fl/fl}* (B) and *N/tv-a;Cdkn2a^{-/-};Pten^{fl/fl}* mice (C). Tumors were generated by the injection of the indicated RCAS virus into neonatal brains. **p* < 0.05, ***p* < 0.005, ****p* < 0.001, *****p* < 0.0001. ns, not significant; ND, not determined.

(D) Representative H&E and immunohistochemical analysis of the PDGFA- and PDGFB-induced gliomas in *N/tv-a;Cdkn2a^{-/-};Pten^{fl/fl}* mice. Boxes denote the enlarged region. Scale bars, 100 μ m.

(E) GSEA of the RCAS-PDGFA- and RCAS-PDGFB-induced gliomas in *N/tv-a;Cdkn2a^{-/-};Pten^{fl/fl}* mice. Gene expression profiles were compared between the PDGFA-induced (*n* = 7) and PDGFB-induced (*n* = 5) gliomas based on the TCGA subtype signatures (Verhaak et al., 2010). Bar plots visualize enrichment *p* values (y axis) of the four subtype signatures in the ranking of genes by differential expression (PDGFA versus PDGFB). A low *p* value indicates consistent expression with the subtype, i.e., many genes known to be upregulated in the subtype are up, and downregulated genes are down.

(F) GSEA of the RCAS-PDGFA/shp53- and RCAS-shNf1/shp53-induced gliomas in *N/tv-a* and *G/tv-a* mice.

See also Figure S4 and Table S7.

in these mice with 100% penetrance and a median survival of 65 days. These tumors demonstrated histological features of human oligodendroglioma and displayed a high-grade histology with uniformly abundant pseudopalisading necrosis, hypervascularity, and brisk microvascular formation throughout the tumor (Figures 4C and 4D; Figure S4I). Interestingly, additional loss of *Pten* in a *Cdkn2a^{-/-}* background did not shorten tumor latency further (Figure 4C).

We then compared gliomas induced by PDGFA and PDGFB in newborn and adult *N/tv-a;Cdkn2a^{-/-}* mice. We found that

PDGFA generated tumors with a longer latency than PDGFB and that gliomas induced by either ligand arose in newborn mice faster than in adults (Figure 4C; Figure S4J) (Squatrolo et al., 2010). The histology of tumors induced by PDGFA and PDGFB was generally similar. However, the vasculature and stroma were notably different (Figure 4D; Figure S4K). PDGFB-induced gliomas showed a spindled vasculature and atypical stroma (PDGFB activates both α receptors in the tumor cells as well as β receptors in the perivascular stroma), whereas tumors generated by PDGFA (which activates only the α receptor)

showed glomeruloid microvascular proliferation more similar to that seen in human GBM (Figure 4D; Figure S4K) (Helmy et al., 2012; Hermansson et al., 1988).

Subsequently, we profiled these tumors by gene expression analysis to determine which human GBM subtype they resembled most closely and found that PDGFA-induced gliomas in the mouse more closely resembled PN GBMs in humans, whereas the PDGFB-induced tumors shifted toward MES GBMs (Figure 4E). The Olig2-expressing tumor cells from PDGFB-induced gliomas, which constitute the bulk of the tumor (Figure 4D), show a strongly proneural expression profile (Dougherty et al., 2012). Therefore, the MES character of the PDGFB-induced gliomas possibly reflects the abundant atypical perivascular stroma and other nontumor stromal cell types found in these tumors (Figures 4D and 4E; Figure S4K).

Loss of *TP53* as well as *PTEN* or *CDKN2A* in PDGFA-Induced Gliomas Results in a Highly Lethal Disease in Mice

CDKN2A loss occurs frequently in human PN GBMs, but this GBM subgroup also commonly harbors mutations in *TP53* (Verhaak et al., 2010). Therefore, we determined whether loss of *TP53* would cooperate with PDGFA-induced gliomas in a similar way as *Cdkn2a* loss. We generated an RCAS vector expressing both mRFP and a short hairpin designed to knock down *TP53* expression (RCAS-shp53) (Figures S4A and S4L–S4P). Infecting mice with this vector alone did not generate gliomas by approximately 1 year of age. However, when combined with RCAS-PDGFA, high-grade gliomas formed in 100% of mice with a median survival of 69.5 days in wild-type *N/tv-a* mice ($n = 18$) and 56 days in wild-type *G/tv-a* mice ($n = 31$), similar to PDGFA in a *Cdkn2a*^{−/−} background (Figures 4A–4C). The tumors demonstrated histological features of human oligodendroglioma and displayed a high-grade histology similar to PDGFA-induced tumors with *Cdkn2a* loss (Figure S4Q). Furthermore, the gene expression profiles of the gliomas induced by PDGFA with loss of *TP53* showed a significant enrichment of PN GBM genes (Figure 4F) as well as downstream orthologs of human PDGFA identified in the abovementioned computational analysis (Figure 3C; Figure S4R; Table S6). These observations suggest that loss of the tumor suppressor genes *PTEN*, *CDKN2A*, or *TP53* is sufficient to enhance PDGFA-induced gliomas, resulting in highly lethal gliomas.

Simultaneous Loss of *Nf1* and *TP53* Induces MES GBM in the RCAS/*tv-a* Model

RESIC analysis predicts that the same early events in PN GBM also occur in MES GBM but that *NF1* loss occurs late in the evolution of these tumors. In MES GBMs (as well as all non-GCIMP GBMs), *NF1* loss is associated with *TP53* mutations and, less commonly, with *CDKN2A* loss (Figure S5A) (Verhaak et al., 2010). Furthermore, published mouse GBM models resulting from germline homozygous deletions of *Nf1* and *TP53* show a median survival of approximately 150–200 days (Reilly et al., 2000; Zhu et al., 2005), but they do not recapitulate a human MES GBM expression pattern (Liu et al., 2011). Other groups recently generated an H-RasV12-shp53 glioma model mimicking *Nf1*/*TP53* loss and reported H-RasV12-shp53-driven GBMs to show MES gene expression (Friedmann-Morvinski

et al., 2012). However, there is no mouse model with *Nf1*/*TP53* loss reported to create a GBM with MES gene expression. More importantly, all of these GBM models were generated using technologies different from what we used, making it difficult to compare them. Therefore, to allow direct comparison of our PDGFA models and mouse models of MES GBM, we engineered the RCAS/*tv-a* system to generate MES GBM from normal cells. We then set out to initially reproduce the published effect of combined loss of *Nf1* and *TP53*.

We created an RCAS vector expressing GFP and a short hairpin designed to knock down *Nf1* expression (RCAS-shNf1) (Figures S4A, S4L, S4N, S4O, S5B, and S5C). Infection of both wild-type *N/tv-a* ($n = 20$) and *G/tv-a* ($n = 12$) mice with this vector alone did not generate tumors by approximately 1 year of age. However, infection with the combination of RCAS-shNf1 and RCAS-shp53 led to the formation of gliomas in 100% of mice, with a median survival of 146 days for *G/tv-a* ($n = 52$) and 221 days for *N/tv-a* ($n = 32$) mice (Figures 5A and 5B; Figures S4O and S5D–S5G). These latencies are similar to those published for gliomas formed by germline models of combined *Nf1* and *p53* loss (Reilly et al., 2000; Zhu et al., 2005). Histologic analysis of the *G/tv-a* and *N/tv-a* tumors showed stronger expression of the MES markers vimentin and CD44, and the MES master regulators pSTAT3 and C/EBP β in the *G/tv-a* tumors than in the *N/tv-a* tumors (Figure 5B and data not shown) (Carro et al., 2010). Gene expression profiling of these tumors (*G/tv-a*, $n = 7$; *N/tv-a*, $n = 11$) demonstrated that they were more MES-like than those driven by PDGFA (Figure 4F) and that gliomas arising in *G/tv-a* mice had a more MES-like expression pattern than those arising in *N/tv-a* mice (Figure 5C). Collectively, these data suggest that it is possible to generate MES gliomas from normal cells in post-natal mice with a similar latency to that seen with germline strategies that delete both genes (Reilly et al., 2000; Zhu et al., 2005). While *Nf1* loss in *N/tv-a*/*Cdkn2a*^{−/−}/*Pten*^{fl/fl} mice was considerably less efficient than loss of *TP53* for the formation of gliomas, as supported by the fact that *NF1* loss is associated with *TP53* mutations and, less commonly, *CDKN2A* loss (Figures S5A and S5E; Table S7) (Verhaak et al., 2010).

Additional Loss of *NF1* Converts the PDGFA-Induced PN Phenotype to a MES Gene Expression Pattern

The tumor latency for PDGFA-induced gliomas versus those induced by *Nf1* loss is striking. In the mouse model, the loss of both *Nf1* and *TP53* occurs simultaneously, whereas in humans, there would be multiple separate mutational events in a normal cell that would lead to loss of function of both alleles of *NF1* and mutation of *TP53*. Such an evolutionary pathway to MES GBMs formation, although possible, might be much slower than that for PN GBMs, which requires elevated expression from a single gene, such as *PDGFA*. Moreover, the importance of the chronological order of mutations in MES glioma formation is underscored by the fact that, in mice, loss of *Nf1* is less efficient at enhancing gliomas than loss of *TP53* in the context of forced PDGFA expression (Figure 4B). Finally, global copy number and RESIC analysis predicts that MES GBMs initially arise from tumors with the same alterations as PN GBMs and that they lose *NF1* later (Figure 2).

Therefore, we sought to determine whether *NF1* loss in PN-GBM could induce a PN-to-MES GBM transition. We obtained




Figure 5. Simultaneous Loss of *Nf1* and *Tp53* Induces MES Gliomas in the RCAS/tv-a Model

(A) Kaplan-Meier survival curves showing symptom-free survival and relative tumor grade of the RCAS-shNf1/shp53-induced gliomas in *N/tv-a* and *G/tv-a* mice. The percentage of tumors exhibiting WHO grade II (G2), III (G3), and IV (GBM) histological features are shown for each genotype.

(B) Representative H&E and immunohistochemical analysis for the indicated protein of the RCAS-shNf1/shp53-induced glioma in *G/tv-a* mice. The box denotes the enlarged region. Scale bars, 100 μ m.

(C) GSEA of the RCAS-shNf1/shp53-induced gliomas in *G/tv-a* and *N/tv-a* mice.

See also Figure S5.

two PN GBM cell lines that contain an amplification of *PDGFRA*, and, by expression profiling, fit the criteria for the PN subtype (Figures 6A and 6B; Figures S6A and S6B) (Ozawa et al., 2010). Expression profiling of the lines before and after *NF1* knockdown showed that the original PN expression pattern was shifted toward a MES or CL pattern in both cases (Figure 6B; Figures S6B and S6C). Moreover, knockdown of *Tp53* or *Nf1* alone was sufficient to induce PN and MES gene enrichment in murine neurosphere culture, respectively (Figure 6C; Figure S6D). These results suggest that *NF1* function regulates transcriptional pathways necessary for mesenchymal conversion. To examine whether *NF1* directly regulates the expression of mesenchymal transcriptional factors (TFs), we performed a TF enrichment analysis in murine neurosphere (Figure S6E), murine glioma (Figure S6F), and TCGA (Figure S6G) data sets. We identified 14 TF gene sets (MSigDB 4.0) corresponding to 9 different TFs, that were significantly ($FDR < 0.05$) associated with *NF1* loss in the three data sets (Figure 6D; Figures S6E–S6G). Some of these

14 TF gene sets associated with *NF1* loss presented a high similarity to each other (Figure 6D) and displayed a significant overlap with recently reported mesenchymal TF target genes (Carro et al., 2010) (Figure 6E). Notably, *NF1* loss was associated significantly with two main mesenchymal TFs, C/EBP β and RUNX1 (Figure 6F). By contrast, perturbations of STAT3 and C/EBP β expression did not affect *NF1* expression in human GBM cells and mouse stem cells (Figures S6H and S6I), implying that these MES-associated TFs are downstream of *NF1* loss. ShNf1-induced tumors showed a statistically significant association between loss of *NF1* and gene expression changes related to the mammalian target of rapamycin (mTOR) pathway (Figure S6J). Furthermore, loss of *NF1* did not appreciably elevate Erk or Akt phosphorylation (p) but did elevate pS6RP, suggesting that *NF1* loss may affect mTOR activity in an Akt-independent manner (Figure 6A). Therefore, we treated the two *NF1* knockdown cell lines with the mTOR inhibitor rapamycin (Figure S6K) and observed a marked but variable shift from MES/CL toward PN




Figure 6. Additional NF1 Loss Induces Proneural-to-Mesenchymal Conversion In Vitro and In Vivo

(A) Western blot analysis of two human GBM cell lines (TS543 and TS667) expressing control shRNA (Ctrl-sh) or NF1 shRNAs (target sequence #2 and #5) with the indicated antibodies.

(B) GSEA of human GBM cell lines. Gene expression profiles were compared between untreated cells, 0.1% DMSO- or 1nM rapamycin-treated cells for 5 hr in two different cell lines (TS543 and TS667) expressing control or NF1 shRNA. Each sample was analyzed in triplicate. Control shRNA samples of the TS543 and TS667 cells also have technical duplicate samples.

(C) GSEA of murine neurosphere lines. The gene expression profiles were analyzed in between *N/tv*-a neurosphere lines expressing RCAS-shGL2, RCAS-shNf1, RCAS-shp53, or RCAS-shNf1/shp53. The subtype gene signature enrichment was determined by comparing the control shRNA sample (shGL2) with each shRNA sample. Each sample was analyzed in triplicate.

(D) The overlap index of the 14 significant gene sets corresponding to 9 different TFs. High overlaps are shown in dark blue.

(E) Cytoscape visualization of the overlap of the 14 significant TF gene sets and the GBM mesenchymal gene signature (Carro et al., 2010). Diamond-shaped nodes represent the 14 TF gene sets. Circular nodes represent TF target genes in both the mesenchymal gene signature and the 14 TF gene sets. TFs and target genes are connected by blue edges. The p value for the overlap of the mesenchymal gene signature and the 14 TFs was 0.005 (hypergeometric distribution).

(F) Correlation of MES-TF expression with NF1 expression in the TCGA Agilent data. p values for anticorrelation with NF1 expression were less than 0.001 for C/EBP β , RUNX1, STAT5A, STAT6, and IRF1.

See also Figure S6.

expression, suggesting that blockade of mTOR rescues the effect of *NF1* loss in PN GBM lines (Figure 6B).

Finally, we determined whether *NF1* loss could convert PN GBMs to MES GBMs in mice. To test sequential loss, we initially generated PDGFA/shp53 tumors by concurrent stereotactic injection of the two vectors and then secondary infection with

the GFP-shNf1 vector into the tumors using the same stereotactic coordinates 2–4 weeks later. The RCAS-GFP-shNf1 virus was incorporated regionally in 15 of 20 mouse gliomas (Table S7). Many of the GFP-positive regions were detected in low PDGFA expression areas and/or the tumor periphery. Higher expression for MES-related markers, such as CD44, pSTAT3, and C/EBP β ,




Figure 7. Additional *Nf1* Loss Induces Proneural-to-Mesenchymal Conversion In Vivo

(A) Representative H&E and immunohistochemical analysis for the indicated protein of the RCAS-PDGFA/shp53-induced glioma secondarily incorporating the RCAS-GFP-shNf1 virus in *G/tv-a* mice. Circles 1 and 2 represent mesenchymal and proneural tumor lesions, respectively. Scale bars, 100 μ m.

(B) Kaplan-Meier survival curves showing symptom-free survival of PDGFA/shp53- or PDGFA/shp53/shNf1-induced gliomas in *N/tv-a* (left panel) and *G/tv-a* (right panel) mice. Tumors were generated by simultaneous injection of the relevant RCAS virus into neonatal pup brains. Survival curves of the RCAS-PDGFA/shp53-induced tumors from Figures 4A and 4B are also shown for comparison. *** $p = 0.0004$, **** $p < 0.0001$.

(C) GSEA of the RCAS-PDGFA/shp53- and RCAS-PDGFA/shp53/shNf1-induced gliomas in *N/tv-a* and *G/tv-a* mice.

was associated preferably with GFP-positive regions (i.e., *Nf1* knockdown) and/or adjacent areas (Figure 7A). For simultaneous loss of *Nf1*, we compared the GBMs generated by the double combination of RCAS-PDGFA and RCAS-shp53 (*G/tv-a*, $n = 31$; *N/tv-a*, $n = 18$; see above) to the triple combination of RCAS-PDGFA, RCAS-shp53, and RCAS-shNf1 (*G/tv-a*, $n = 26$; *N/tv-a*, $n = 18$). The additional loss of *Nf1* in the triply infected mice resulted in gliomas occurring significantly faster than the doubly infected mice, both from the *G/tv-a* (Figure 7B, right panel) and the *N/tv-a* (Figure 7B, left panel) cell of origin. The expression patterns for the two populations showed that the doubly infected mice generated gliomas with a PN gene expression pattern (Figures 4F and 7C), whereas the gliomas from the triply infected mice shifted toward MES (Figure 7C).

DISCUSSION

There has been much discussion about the implications of the molecular subgroups of GBM. The data presented here connect the GBM subtypes in an evolutionary framework where the primordial tumors are PN in character, with the other subgroups evolving from them. Amplification of *PDGFRA* occurs primarily in tumors that remain PN. Mathematical modeling suggests that chr7 gain and chr10 loss are very common early genetic

events in all subtypes of non-GCIMP GBM. Further, we found that the selective advantage for additional copies of chr7 is primarily, but potentially not exclusively, driven by elevated expression of *PDGFA* and that a primary driver for loss of chr10 is reduced expression of *PTEN*. These predictions were supported by mouse modeling data indicating that overexpression of *PDGFA* was sufficient to induce gliomas that were enhanced by *PTEN* loss to give rise to GBM with a PN character. Note that chr7 encodes many other genes with elevated copy number by the gain of chr7, which may contribute to oncogenesis and therapeutic resistance. Similarly, there could be genes on chr10 additional to *PTEN* whose loss enhances oncogenesis or alters the therapeutic response early in GBM evolution.

Loss of chr10, which occurs in nearly all non-GCIMP GBMs, is represented by one copy loss. Therefore, it is intriguing to know whether loss of function of the remaining allele is essential in non-GCIMP GBM formation. A nonsilent somatic point mutation in the remaining *PTEN* allele is found in 37.9% of all cases with a single copy of chr10, and homozygous deletion was identified in 10% of non-GCIMP GBMs. Given that *PTEN* expression is also regulated by promoter methylation and microRNA, the remaining *PTEN* allele might be also inactivated by alternative mechanisms in non-GCIMP GBMs (Baeza et al., 2003; Huse et al., 2009; Wiencke et al., 2007). Furthermore, the level of *PTEN* mRNA

expression decreased from diploid to hemi- and homozygous loss in non-GCIMP GBMs. In mice, heterozygous loss of *Pten* was sufficient to induce gliomas in combination with *Tp53* loss, with or without *Nf1* loss, and the homozygous loss increased the aggressiveness of tumors (Kwon et al., 2008; Zheng et al., 2008). Therefore, heterozygous loss of *PTEN* appears to be enough for initiating an abrogation of gene function in GBM patients.

Mouse models can demonstrate that specific cell types, gene combinations, and sequences of events are sufficient to form tumors, but they alone do not prove that human tumors form that way. The mathematical analysis of human GBM data presented here indicates that a specific set and order of gene abnormalities represent the major evolutionary pathway toward non-GCIMP GBM. The mouse modeling shows that this specific predicted series of events is sufficient to form PN-like GBM in mice and that this character can be shifted to a MES one with subsequent loss of *Nf1*, predicted to be a late event in the evolution of MES GBM in humans. Further, given the highly similar copy number patterns for most non-GCIMP GBM subtypes, it is likely that most non-GCIMP GBM subtypes arise similarly.

Our studies suggest that cells harboring both chr7 gain and chr10 loss are the most likely cells of origin for gliomas. However, given the existence of a few cases of GBM in the TCGA data set without copy number alterations of both chromosomes, there clearly are exceptions. Indeed, as shown by our *Nf1/Tp53* loss model, it is possible that MES GBMs could arise de novo via a different cell of origin and evolutionary pathway. Furthermore, the relatively rare patients without chr10 loss have significantly more whole chromosome 12 gains (FDR < 0.01), and patients without chr7 gain have significantly higher odds of a *PDGFRA* somatic mutation ($p = 0.05$, Fisher's exact test). This might also indicate that pathways affected by chr7 gain and chr10 loss can be interrupted with similar consequences by alterations on other chromosomes. Nonetheless, the majority of non-GCIMP GBMs are abnormal for chr7 and chr10 and most likely arise from a PN-like precursor lesion.

This series of molecular events early in the development of GBM is different from that seen in other cancer types induced by point mutations or translocations with the generation of a single oncogene in an otherwise normal background, such as chronic myeloid leukemia (Hehlmann et al., 2007). The acquisition of multiple pro-oncogenic alterations by copy number gain and loss at the outset of tumor formation would reduce the likelihood of success for targeted therapy against any specific signaling targets, especially those acquired late in the tumor's evolution. The data argue that *PDGFA* is the gene on chr7 that most likely provides the strongest selection for initial gain of chr7 at the beginning of non-GCIMP GBM formation. However, other genes on chr7, such as *CUL1*, *CBLL1*, *ASNS*, *ARPC1A*, and *GLI3*, might have similar but less robust effects and could collectively trump *PDGFA* expression later in GBM evolution. It remains to be elucidated how our findings relate to other tumor types that also show gains of large portions of chr7 and loss of chr10.

The chromosomal abnormalities early during GBM evolution are interesting in light of the observation that aneuploidy for at least one chromosome occurs in as many as 10% of all cells in the normal adult brain (Iourov et al., 2006; Iourov et al., 2009) and is even higher during development, reaching 30%–35%

(Bushman and Chun, 2013; Yurov et al., 2007). This higher prevalence in the brain compared with other organs has been suggested to contribute to neuronal diversity (Bushman and Chun, 2013). However, from this diverse set of errors in chromosomal number throughout the normal brain, only cells with loss of one copy of chr10 and gain of variable numbers of chr7 give rise to non-GCIMP GBMs. Given the prevalence of aneuploid cells in the normal brain, it is likely that many cells with both gain of chr7 and loss of chr10 exist in each individual. Therefore, other mechanisms may contribute to the fact that GBMs are not more prevalent. If aneuploidy in the CNS functions to generate neuronal diversity, we might speculate that the risk of developing GBM may be the price paid for complex CNS function.

EXPERIMENTAL PROCEDURES

Data Sets of Human GBM Samples

We obtained segmented copy number data, raw and normalized mRNA expression data, methylation data, and somatic mutation data from the TCGA (The Cancer Genome Atlas Research Network, 2008). All analyses were done in R/Bioconductor (Gentleman et al., 2004). The details of all bioinformatic analyses are described in the Supplemental Experimental Procedures.

Phylogenetic Analysis

To examine the relationship between GBM subgroups, we applied the Neighbor-Joining algorithm (Saitou and Nei, 1987) independently to the TCGA GBM Agilent expression, SNP copy number, promoter methylation, and somatic mutation data, as described previously (Riester et al., 2010).

RESIC Analysis

To determine the temporal sequence of genetic alterations, two whole chromosome events, chr7 non-disjunction and chr10 loss, as well as subtype-defining events (focal *EGFR* gain and amplification, *PDGFRA* gain and amplification, and *NF1* loss), we applied the RESIC algorithm to the GBM data set, as described previously (Attolini et al., 2010; Cheng et al., 2012).

Pathway Analysis

To prioritize genes in large copy number alterations, we developed a computational method. The algorithm identifies genes from disease-related pathways for which copy number gain has a profound impact on mRNA levels.

Transcription Factor Analysis

To examine whether *NF1* loss had an impact on expression of certain TFs, a gene set enrichment analysis (GSEA) was performed with MSigDB 4.0, which provides 615 putative TF/target gene sets (c3 category) (Subramanian et al., 2005).

Gene Expression Analysis for Murine Brain Tumors and Neurosphere and Human GBM Cell Lines

Total RNAs were labeled by the Illumina protocol, followed by hybridization to the BeadChip (Illumina). Raw data were processed at the Genomics Core Laboratory of Memorial Sloan-Kettering Cancer Center (MSKCC) and then normalized with the lumi R package (Du et al., 2008). For the GSEA, the Verhaak et al. subtype signatures were used (Verhaak et al., 2010).

Vector Constructs

The human *PDGFA* cDNA was purchased from OriGene Technologies and was subcloned into the RCAS-Y vector (Dunn et al., 2000). For the generation of the RCAS-shRNA vector, shRNAs were initially assembled in the pSUPER.retro.puro vector (OligoEngine) or the pENTR-mRFP-H1 vector. The shRNAs containing the H1 promoter were PCR-amplified and then inserted into the RCAS-Y vector. For the pENTR-mRFP-H1 vector, LR recombination was used to transfer the shRNA containing H1 and mRFP into the RCAS-Destination vector (Loftus et al., 2001) (see also Supplemental Experimental Procedures).

Generation of Murine Brain Tumors

All animal experiments were done in accordance with protocols approved by the Institutional Animal Care and Use Committees of MSKCC and Fred Hutchinson Cancer Research Center and followed NIH guidelines for animal welfare. The RCAS/tv-a system used in this work has been described previously (Holland et al., 1998, 2000; Holland and Varmus, 1998; Hu et al., 2005; Uhrbom et al., 2004). *GFAP (G)/tv-a, G/tv-a;Pten^{fl/fl}, G/tv-a^{+/-};Tg-Ef luc, Nestin (N)/tv-a* (agouti), or *N/tv-a;Cdkn2a(Ink4a-Arf)^{-/-};Pten^{fl/fl}* mice were used for the RCAS-mediated gliomagenesis in this study. After injection of the relevant RCAS virus, mice were observed until they developed brain tumor-related symptoms unless there was a particular note (see also Supplemental Experimental Procedures).

Hematoxylin and Eosin Staining and Immunohistochemistry

Mouse brains were prepared for paraffin and sectioning and stained with hematoxylin and eosin as described previously (Hambardzumyan et al., 2009; Holland et al., 2000). Briefly, immunohistochemical staining was performed with an automated staining processor (Hambardzumyan et al., 2008). The antibodies used in this study are described in the Supplemental Experimental Procedures. The histological diagnosis and tumor grade was established based on the World Health Organization (WHO) criteria (Huse et al., 2009; Louis et al., 2007).

Western Blot Analysis

Cells were cultured, lysed with NF1 lysis buffer (Yunoue et al., 2003), and processed for Western blotting by standard methods. The antibodies used in this study are described in the Supplemental Experimental Procedures.

ACCESSION NUMBERS

All microarray data were deposited in the Gene Expression Omnibus under accession number GSE45874.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, six figures, and seven tables and can be found with this article online at <http://dx.doi.org/10.1016/j.ccr.2014.06.005>.

ACKNOWLEDGMENTS

We thank Robert “Jim” Finney and Qunchao Zhang for technical assistance; Amanda Conlon, Christine Ferreira, Jenny Zhang, Raquel Sanchez, and Desert Horse-Grant for secretarial assistance; Jeffrey Zhao, Maryam Hassimi, and Agnes Viale for microarray analysis; and members of the E.C.H. and F.M. laboratories, Dr. Armida Fabius, Dr. Shigehisa Kitano, Dr. Atsushi Kawaguchi, Dr. Tatsuyuki Kakuma, and Dr. Mitsutoshi Nakada for helpful discussions. The results in this article are analyzed using data generated by the TCGA project (<http://cancergenome.nih.gov>). We thank Dr. Hideyuki Saya and Dr. Shinji Kuninaka, Keio University, for the pSUPER-GL2, Nf1, and p53 shRNA constructs and Dr. Cameron Brennan for the human GBM cell lines. This work was supported by 2009 and 2010 Brain Tumor Center Grants, MSKCC (to T.O.); NIH grants U54CA163167-01, U01CA141502-01, and R01CA100688 (to E.C.H.), and 2009 and 2010 U54CA143798 Grant (to F.M. and E.C.H.).

Received: October 27, 2013

Revised: February 20, 2014

Accepted: June 11, 2014

Published: August 11, 2014

REFERENCES

Andrae, J., Gallini, R., and Betsholtz, C. (2008). Role of platelet-derived growth factors in physiology and medicine. *Genes Dev.* 22, 1276–1312.

Attolini, C.S., Cheng, Y.K., Beroukhi, R., Getz, G., Abdel-Wahab, O., Levine, R.L., Mellinghoff, I.K., and Michor, F. (2010). A mathematical framework to determine the temporal sequence of somatic genetic events in cancer. *Proc. Natl. Acad. Sci. USA* 107, 17604–17609.

Baeza, N., Weller, M., Yonekawa, Y., Kleihues, P., and Ohgaki, H. (2003). PTEN methylation and expression in glioblastomas. *Acta Neuropathol.* 106, 479–485.

Beerenwinkel, N., and Sullivant, S. (2009). Markov models for accumulating mutations. *Biometrika* 96, 645–661.

Bhat, K.P., Balasubramanian, V., Vaillant, B., Ezhilarasan, R., Hummelink, K., Hollingsworth, F., Wani, K., Heathcock, L., James, J.D., Goodman, L.D., et al. (2013). Mesenchymal differentiation mediated by NF- κ B promotes radiation resistance in glioblastoma. *Cancer Cell* 24, 331–346.

Brennan, C., Momota, H., Hambardzumyan, D., Ozawa, T., Tandon, A., Pedraza, A., and Holland, E. (2009). Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. *PLoS ONE* 4, e7752.

Bushman, D.M., and Chun, J. (2013). The genomically mosaic brain: aneuploidy and more in neural diversity and disease. *Semin. Cell Dev. Biol.* 24, 357–369.

Cancer Genome Atlas Research Network (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 455, 1061–1068.

Carro, M.S., Lim, W.K., Alvarez, M.J., Bollo, R.J., Zhao, X., Snyder, E.Y., Sulman, E.P., Anne, S.L., Doetsch, F., Colman, H., et al. (2010). The transcriptional network for mesenchymal transformation of brain tumours. *Nature* 463, 318–325.

Cheng, Y.K., Beroukhi, R., Levine, R.L., Mellinghoff, I.K., Holland, E.C., and Michor, F. (2012). A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis. *PLoS Comput. Biol.* 8, e1002337.

Dai, C., Celestino, J.C., Okada, Y., Louis, D.N., Fuller, G.N., and Holland, E.C. (2001). PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. *Genes Dev.* 15, 1913–1925.

Dougherty, J.D., Fomchenko, E.I., Akuffo, A.A., Schmidt, E., Helmy, K.Y., Bazzoli, E., Brennan, C.W., Holland, E.C., and Milosevic, A. (2012). Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma. *Cancer Res.* 72, 4856–4868.

Du, P., Kibbe, W.A., and Lin, S.M. (2008). lumi: a pipeline for processing Illumina microarray. *Bioinformatics* 24, 1547–1548.

Dunn, K.J., Williams, B.O., Li, Y., and Pavan, W.J. (2000). Neural crest-directed gene transfer demonstrates Wnt1 role in melanocyte expansion and differentiation during mouse development. *Proc. Natl. Acad. Sci. USA* 97, 10050–10055.

Fomchenko, E.I., Dougherty, J.D., Helmy, K.Y., Katz, A.M., Pietras, A., Brennan, C., Huse, J.T., Milosevic, A., and Holland, E.C. (2011). Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression. *PLoS ONE* 6, e20605.

Friedmann-Morvinski, D., Bushong, E.A., Ke, E., Soda, Y., Marumoto, T., Singer, O., Ellisman, M.H., and Verma, I.M. (2012). Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. *Science* 338, 1080–1084.

Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004). Bioconductor: open software development for computational biology and bioinformatics. *Genome Biol.* 5, R80.

Hambardzumyan, D., Becher, O.J., Rosenblum, M.K., Pandolfi, P.P., Manova-Todorova, K., and Holland, E.C. (2008). PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. *Genes Dev.* 22, 436–448.

Hambardzumyan, D., Amankulor, N.M., Helmy, K.Y., Becher, O.J., and Holland, E.C. (2009). Modeling Adult Gliomas Using RCAS/tv-a Technology. *Transl. Oncol.* 2, 89–95.

Hehlmann, R., Hochhaus, A., and Baccarani, M.; European LeukemiaNet (2007). Chronic myeloid leukaemia. *Lancet* 370, 342–350.

Heldin, C.H., and Westermark, B. (1999). Mechanism of action and in vivo role of platelet-derived growth factor. *Physiol. Rev.* 79, 1283–1316.

- Helmy, K., Halliday, J., Fomchenko, E., Setty, M., Pitter, K., Hafemeister, C., and Holland, E.C. (2012). Identification of global alteration of translational regulation in glioma in vivo. *PLoS ONE* 7, e46965.
- Hermansson, M., Nistér, M., Betsholtz, C., Heldin, C.H., Westermark, B., and Funai, K. (1988). Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. *Proc. Natl. Acad. Sci. USA* 85, 7748–7752.
- Holland, E.C., and Varmus, H.E. (1998). Basic fibroblast growth factor induces cell migration and proliferation after glia-specific gene transfer in mice. *Proc. Natl. Acad. Sci. USA* 95, 1218–1223.
- Holland, E.C., Hively, W.P., DePinho, R.A., and Varmus, H.E. (1998). A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. *Genes Dev.* 12, 3675–3685.
- Holland, E.C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R.E., and Fuller, G.N. (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. *Nat. Genet.* 25, 55–57.
- Hu, X., Pandolfi, P.P., Li, Y., Koutcher, J.A., Rosenblum, M., and Holland, E.C. (2005). mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. *Neoplasia* 7, 356–368.
- Huse, J.T., Brennan, C., Hambarzumyan, D., Wee, B., Pena, J., Rouhanifard, S.H., Sohn-Lee, C., le Sage, C., Agami, R., Tuschl, T., and Holland, E.C. (2009). The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. *Genes Dev.* 23, 1327–1337.
- Iourov, I.Y., Liehr, T., Vorsanova, S.G., Kolotii, A.D., and Yurov, Y.B. (2006). Visualization of interphase chromosomes in postmitotic cells of the human brain by multicolour banding (MCB). *Chromosome Res.* 14, 223–229.
- Iourov, I.Y., Vorsanova, S.G., Liehr, T., and Yurov, Y.B. (2009). Aneuploidy in the normal, Alzheimer's disease and ataxia-telangiectasia brain: differential expression and pathological meaning. *Neurobiol. Dis.* 34, 212–220.
- Jackson, E.L., Garcia-Verdugo, J.M., Gil-Perotin, S., Roy, M., Quinones-Hinojosa, A., VandenBerg, S., and Alvarez-Buylla, A. (2006). PDGFR alpha-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. *Neuron* 51, 187–199.
- Kwon, C.H., Zhao, D., Chen, J., Alcantara, S., Li, Y., Burns, D.K., Mason, R.P., Lee, E.Y., Wu, H., and Parada, L.F. (2008). Pten haploinsufficiency accelerates formation of high-grade astrocytomas. *Cancer Res.* 68, 3286–3294.
- Lengauer, C., Kinzler, K.W., and Vogelstein, B. (1998). Genetic instabilities in human cancers. *Nature* 396, 643–649.
- Liu, C., Sage, J.C., Miller, M.R., Verhaak, R.G., Hippenmeyer, S., Vogel, H., Foreman, O., Bronson, R.T., Nishiyama, A., Luo, L., and Zong, H. (2011). Mosaic analysis with double markers reveals tumor cell of origin in glioma. *Cell* 146, 209–221.
- Loftus, S.K., Larson, D.M., Watkins-Chow, D., Church, D.M., and Pavan, W.J. (2001). Generation of RCAS vectors useful for functional genomic analyses. *DNA Res.* 8, 221–226.
- Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvett, A., Scheithauer, B.W., and Kleihues, P. (2007). The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol.* 114, 97–109.
- Nazarenko, I., Hedrén, A., Sjödin, H., Orrego, A., Andrae, J., Afink, G.B., Nistér, M., and Lindström, M.S. (2011). Brain abnormalities and glioma-like lesions in mice overexpressing the long isoform of PDGF-A in astrocytic cells. *PLoS ONE* 6, e18303.
- Noushmehr, H., Weisenberger, D.J., Diefes, K., Phillips, H.S., Pujara, K., Berman, B.P., Pan, F., Pelloski, C.E., Sulman, E.P., Bhat, K.P., et al.; Cancer Genome Atlas Research Network (2010). Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell* 17, 510–522.
- Ohgaki, H., and Kleihues, P. (2013). The definition of primary and secondary glioblastoma. *Clin. Cancer Res.* 19, 764–772.
- Ozawa, T., Brennan, C.W., Wang, L., Squatrito, M., Sasayama, T., Nakada, M., Huse, J.T., Pedraza, A., Utsuki, S., Yasui, Y., et al. (2010). PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. *Genes Dev.* 24, 2205–2218.
- Phillips, H.S., Kharbanda, S., Chen, R., Forrest, W.F., Soriano, R.H., Wu, T.D., Misra, A., Nigro, J.M., Colman, H., Soroceanu, L., et al. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. *Cancer Cell* 9, 157–173.
- Reilly, K.M., Loisel, D.A., Bronson, R.T., McLaughlin, M.E., and Jacks, T. (2000). Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. *Nat. Genet.* 26, 109–113.
- Riester, M., Stephan-Otto Attolini, C., Downey, R.J., Singer, S., and Michor, F. (2010). A differentiation-based phylogeny of cancer subtypes. *PLoS Comput. Biol.* 6, e1000777.
- Saitou, N., and Nei, M. (1987). The neighbor-joining method: a new method for reconstructing phylogenetic trees. *Mol. Biol. Evol.* 4, 406–425.
- Shih, A.H., Dai, C., Hu, X., Rosenblum, M.K., Koutcher, J.A., and Holland, E.C. (2004). Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis. *Cancer Res.* 64, 4783–4789.
- Sottoriva, A., Spiteri, I., Piccirillo, S.G., Touloumis, A., Collins, V.P., Marioni, J.C., Curtis, C., Watts, C., and Tavaré, S. (2013). Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. *Proc. Natl. Acad. Sci. USA* 110, 4009–4014.
- Squatrito, M., Brennan, C.W., Helmy, K., Huse, J.T., Petrini, J.H., and Holland, E.C. (2010). Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. *Cancer Cell* 18, 619–629.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* 102, 15545–15550.
- Uhrbom, L., Nerio, E., and Holland, E.C. (2004). Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. *Nat. Med.* 10, 1257–1260.
- Verhaak, R.G., Hoadley, K.A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M.D., Miller, C.R., Ding, L., Golub, T., Mesirov, J.P., et al.; Cancer Genome Atlas Research Network (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell* 17, 98–110.
- Wiencke, J.K., Zheng, S., Jelluma, N., Tihan, T., Vandenberg, S., Tamgüney, T., Baumber, R., Parsons, R., Lamborn, K.R., Berger, M.S., et al. (2007). Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. *Neuro-oncol.* 9, 271–279.
- Yunoue, S., Tokuo, H., Fukunaga, K., Feng, L., Ozawa, T., Nishi, T., Kikuchi, A., Hattori, S., Kuratsu, J., Saya, H., and Araki, N. (2003). Neurofibromatosis type I tumor suppressor neurofibromin regulates neuronal differentiation via its GTPase-activating protein function toward Ras. *J. Biol. Chem.* 278, 26958–26969.
- Yurov, Y.B., Iourov, I.Y., Vorsanova, S.G., Liehr, T., Kolotii, A.D., Kutsev, S.I., Pellestor, F., Beresheva, A.K., Demidova, I.A., Kravets, V.S., et al. (2007). Aneuploidy and confined chromosomal mosaicism in the developing human brain. *PLoS ONE* 2, e558.
- Zheng, H., Ying, H., Yan, H., Kimmelman, A.C., Hiller, D.J., Chen, A.J., Perry, S.R., Tonon, G., Chu, G.C., Ding, Z., et al. (2008). p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. *Nature* 455, 1129–1133.
- Zhu, Y., Guignard, F., Zhao, D., Liu, L., Burns, D.K., Mason, R.P., Messing, A., and Parada, L.F. (2005). Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. *Cancer Cell* 8, 119–130.
- Zhu, H., Acquaviva, J., Ramachandran, P., Boskovic, A., Woolfenden, S., Pfannl, R., Bronson, R.T., Chen, J.W., Weissleder, R., Housman, D.E., and Charest, A. (2009). Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. *Proc. Natl. Acad. Sci. USA* 106, 2712–2716.